WuXi XDC

Overview

WuXi XDC is a Contract Research, Development and Manufacturing Organization (CRDMO) specializing in antibody drug conjugates (ADCs) and broader bioconjugates. The company operates as a single-source platform with integrated, end-to-end capabilities across discovery, development, and cGMP manufacturing.

Key Capabilities

Bioconjugation Services:

• Bioconjugation discovery with R&D capabilities for ADC/bioconjugate generation, engineering, evaluation, and optimization
• Bioconjugation process development, scale-up, and tech-transfer to GMP manufacturing
• mAb intermediate and conjugation manufacturing from development batches through clinical and commercial supply

Drug Product Development & Manufacturing:

• Formulation and drug product development for liquid, frozen, and lyophilized dosage forms
• GMP formulation, fill, and lyophilization services with fully automated, isolator-based aseptic systems
• Vial filling capability for 2R, 6R, 10R, 20R, and 50R sizes for ADCs, bioconjugates, cytotoxic compounds, and small molecules

Chemical Intermediates:

• Payload and linker R&D and cGMP manufacturing for client-specified custom chemical intermediates
• Ready-to-conjugate off-the-shelf chemical payloads, linkers, and payload-linker intermediates

Analytical & Supporting Services:

• Analytical development with in-house expertise and state-of-the-art equipment
• Bioassay and biosafety laboratories supporting all development stages
• Characterization of protein/mAb, payload, linker, and bioconjugate intermediates

Market Position

WuXi XDC serves over 500 clients worldwide with more than 200 ongoing integrated CMC development programs and over 30 late-stage Phase II/III programs. The company has enabled over 100 successful INDs filed by clients. The proximity of facilities (within 1-2 hours drive) enables streamlined development that cuts development and manufacturing timelines in half.